By Hannah Albarazi ( March 30, 2021, 9:35 PM EDT) -- Martin Shkreli dropped demands for a jury trial on Tuesday and, in exchange, seven U.S. states agreed not to seek civil penalties or forfeitures in a Federal Trade Commission-led lawsuit, which claims the former biopharma executive and his company Vyera blocked rivals from developing generic versions of the anti-parasite drug Daraprim....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.